For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Nichi-Iko, South Korean Biotech Firm Partner Up on Biosimilar Business
October 3, 2013
- Nihon Chouzai to Increase Its Generic Portfolio to 1,000 in 2 Years: President Mitsuhara
October 3, 2013
- Asahi Kasei Pharma, Vernalis Sign Joint Research Agreement for New Drug Discoveries for Autoimmune Diseases
October 3, 2013
- Kissei, JCR to Jointly Develop Nesp Biosimilar
October 2, 2013
- Another Administrative Action Taken Against MTPC on Medway Injection; 3rd in 4 Years
October 2, 2013
- US FDA Approves Brintellix for Treatment of MDD in Adults: Takeda, Lundbeck
October 2, 2013
- Asahi Kasei Pharma, Pfizer Japan Strike Copromotion Deal for Recomodulin
October 2, 2013
- Nichi-Iko to Take Over Astellas’s Shizuoka Plant Next April
October 1, 2013
- Takeda Files for Approval of Hib Vaccine in Japan
October 1, 2013
- Amgen Astellas BioPharma to Go on Stream Oct. 1; JV Chief Takahashi Eager to Make It a “Category Leader”
September 30, 2013
- Luseogliflozin in Domestic PIII Study Significantly Reduces HbA1c: Taisho Pharmaceutical
September 27, 2013
- Nippon Shinyaku, Fuji Pharma Launch Lunabell Tablets ULD
September 27, 2013
- Maruho to Turn Maeda Pharmaceutical into Subsidiary, Expand Production Capability
September 26, 2013
- 3 Pharma Groups Demand Permanent Introduction of Premium at CSIMC; Healthcare Rep Still Wary
September 26, 2013
- Merck, NCC Tie Up in Cancer Drug R&D for Asian Patients
September 26, 2013
- Cancer Pain Reliever E-fen Buccal Tablets Launched: Taiho, Teikoku Seiyaku
September 26, 2013
- Daiichi Sankyo Dogged by Renewed Quality Woes at Ranbaxy; FDA Mute on Details
September 26, 2013
- Pfizer Japan’s Termination of CMR Agreement a Setback for Quintiles
September 25, 2013
- 1st ADC Kadcyla Approved for HER2-Positive Breast Cancer: Chugai
September 25, 2013
- Unique Marketing System Jacks Up Profits at Vital KSK; Customer-by-Customer Cost Analyses Lend Support
September 24, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…